Amalus Therapeutics develops innovative approach for treating patients with cancer or fibrotic diseases
Ghent University and the booming Ghent biotech landscape welcome a brand new spin-off: Amalus Therapeutics is developing a new class of drugs that selectively target corrupt fibroblast cells.
United Kingdom Bart Roman Christian Stevens Oxford Business Network Novo Nordisk Foundation Ghent University
Source: news-medical.net